标题
Monoclonal antibodies in treatment of multiple sclerosis
作者
关键词
-
出版物
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 175, Issue 3, Pages 373-384
出版商
Wiley
发表日期
2013-09-04
DOI
10.1111/cei.12197
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy
- (2014) Daniel L. Keene et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
- (2014) Manabu Araki et al. Modern Rheumatology
- Immunology of neuromyelitis optica: a T cell-B cell collaboration
- (2013) Meike Mitsdoerffer et al. Annals of the New York Academy of Sciences
- Multiple sclerosis treatment and infectious issues: update 2013
- (2013) A. Winkelmann et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Requirement for safety monitoring for approved multiple sclerosis therapies: an overview
- (2013) P. S. Rommer et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
- (2013) Gilles Edan et al. CNS DRUGS
- The benefits and risks of alemtuzumab in multiple sclerosis
- (2013) Daniel Ontaneda et al. Expert Review of Clinical Immunology
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
- (2013) Stefanie Dahlhaus et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
- (2013) Sean J Pittock et al. LANCET NEUROLOGY
- Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy
- (2013) Ilya Ayzenberg et al. JAMA Neurology
- The Role of Natural Killer Cells in Multiple Sclerosis and Their Therapeutic Implications
- (2013) Coralie Chanvillard et al. Frontiers in Immunology
- Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
- (2012) Paulus S. Rommer et al. CURRENT PHARMACEUTICAL DESIGN
- Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab
- (2012) S. Rossi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Progressive multifocal leukoencephalopathy in autoimmune diseases
- (2012) Elisabeth Palazzo et al. JOINT BONE SPINE
- Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
- (2012) Joachim Havla et al. JOURNAL OF NEUROLOGY
- Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab
- (2012) B.K. Kleinschmidt-DeMasters et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
- (2012) L Daelman et al. Multiple Sclerosis Journal
- Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings
- (2012) F Rinaldi et al. Multiple Sclerosis Journal
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica
- (2012) Bernd C. Kieseier et al. JAMA Neurology
- The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis
- (2012) Isabela T. Borges et al. Multiple Sclerosis and Related Disorders
- Rituximab for Secondary Progressive Multiple Sclerosis
- (2011) Paulus S. Rommer et al. CNS DRUGS
- More to come: Humoral immune responses in MS
- (2011) Ruth Dobson et al. JOURNAL OF NEUROIMMUNOLOGY
- Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis
- (2011) Ying Li et al. JOURNAL OF NEUROIMMUNOLOGY
- Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study
- (2011) María José Magraner et al. JOURNAL OF NEUROLOGY
- De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate
- (2011) Joachim Havla et al. JOURNAL OF NEUROLOGY
- Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
- (2011) A. Kerbrat et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Intrathecal effects of daclizumab treatment of multiple sclerosis
- (2011) B. Bielekova et al. NEUROLOGY
- Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
- (2011) M. Cossburn et al. NEUROLOGY
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
- (2011) Norio Chihara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
- (2011) Hans-Peter Tony et al. ARTHRITIS RESEARCH & THERAPY
- Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated
- (2010) Joep Killestein et al. ANNALS OF NEUROLOGY
- Natalizumab dosage suspension: Are we helping or hurting?
- (2010) Timothy W. West et al. ANNALS OF NEUROLOGY
- MS and the B cell controversy
- (2010) Anne H. Cross et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- T helper 17 cells: discovery, function, and physiological trigger
- (2010) Miriam Beer Torchinsky et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material
- (2010) J. S. CROWE et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis
- (2010) Brandon A. Brown et al. DRUG SAFETY
- The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis
- (2010) Aaron Boster et al. DRUGS
- Alemtuzumab and multiple sclerosis: therapeutic application
- (2010) Minagar Alireza et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
- (2010) Daniel Wynn et al. LANCET NEUROLOGY
- Ofatumumab
- (2010) Bodi Zhang mAbs
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
- (2010) R. T. Naismith et al. NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
- (2009) Bibiana Bielekova et al. ARCHIVES OF NEUROLOGY
- Immune reconstitution syndrome and the thyroid
- (2009) Anthony Weetman BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Ocrelizumab: a step forward in the evolution of B-cell therapy
- (2009) Fariha Kausar et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Monoclonal antibodies in the therapy of multiple sclerosis
- (2009) P. S. Rommer et al. JOURNAL OF NEUROLOGY
- Long-term daclizumab therapy in relapsing-remitting multiple sclerosis
- (2009) Monica A. Rojas et al. Therapeutic Advances in Neurological Disorders
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Monoclonal Antibodies as Innovative Therapeutics
- (2008) Janice Reichert CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Anti–Glomerular Basement Membrane Disease after Alemtuzumab
- (2008) Menna R. Clatworthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now